Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer

Cancer

Volumn 107, Issue 7, 2006, Pages 1459-1466

  Rouzier, Roman ^a,b,c   Pusztai, Lajos ^a   Garbay, Jean Remi ^b   Delaloge, Suzette ^b   Hunt, Kelly K ^a   Hortobagyi, Gabriel N ^a   Berry, Donald ^a   Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL TENON   (France)

Author keywords

Breast cancer; Breast conservation; Neoadjuvant chemotherapy; Nomogram

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER STAGING; COMPUTER PROGRAM; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MINIMAL RESIDUAL DISEASE; NOMOGRAM; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR VOLUME; UNITED STATES; VALIDATION STUDY;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; NOMOGRAMS; PACLITAXEL; PROBABILITY; PROGNOSIS; SOFTWARE; TREATMENT OUTCOME;

EID: 33749590015     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22177     Document Type: Article

References (22)

1. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004:100:2512-2532.
2. Mauri D, Pavlidis N, Ioannidis JR Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188-194.
3. Rouzier R, Mathieu MC, Sideris L, et al. Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer. 2004;101:918-925.
4. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002;9:228-234.
5. Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol. 2002;20:108-115.
6. Kattan MW, Giri D, Panageas KS, et al. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer. 2004;101:2509-2515.
7. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140-1151.
8. Valero V, Buzdar AU, McNeese M, et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002;3(Suppl 2):S63-68.
9. Huang EH, Tucker SL, Strom EA, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:351-357.
10. Contesso G, Mouriesse H, Friedman S, et al. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave Roussy. J Clin Oncol. 1987;5:1378-1386.
11. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988;6:1076-1087.
12. Cox DR. Two further applications of a model for binary regression. Biometrika. 1958;45:562-565.
13. David C, Plummer M, Carstensen B, et al. Epi: a package for statistical analysis in epidemiology. R package version 0.2. 2005. Available at URL: http://www.pubhealth.ku.dk/~bxc/Epi/ [accessed August 8, 2006].
14. Harrell F Jr., Frank E. Regression Modeling Strategies, With Applications to Linear Models. Logistic Regression, and Survival analysis. New York: Springer; 2001.
15. Harrell F Jr., Frank E. Hmisc: A Package of Miscellaneous S Functions. Nashville, TN: Vanderbilt University; 2005. Available at URL: http://biostat.mc.vanderbilt.edu/s/Hmisc [accessed August 8, 2006].
16. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005. Available at URL: http://www. R-project.org [accessed August 8, 2006].
17. Meyer JS, Alvarez C, Milikowski C, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18:1067-1078.
18. Locker GY, Sainsbury JR, Cuzick J. Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer. 2004;101: 735-740.
19. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22:4958-4965.
20. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69-S74.
21. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-2027.
22. Rouzier R, Puszai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23:8331-9.